1 recruiting, 1 suspended, 1 terminated. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Suspended 1 |
Follow Pancreatic Acinar Carcinoma: new trials by email Literature Review of Pancreatic Acinar Carcinoma trials Research Report on Pancreatic Acinar Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer SNV1521, daraxonrasib - Pancreatic Cancer, Pancreatic Acinar Carcinoma | Phase 1 | Recruiting | ParVation Therapeutics, Inc. | 40 | 2026-09-01 | 2026-10-27 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| Acelarin First Line Randomised Pancreatic Study Acelarin, Gemcitabine - Pancreatic Acinar Carcinoma, Pancreatic Neoplasms | Phase 2 / Phase 3 | Suspended | The Clatterbridge Cancer Centre NHS Foundation Trust | 328 | 2015-12-01 | 2019-10-29 |
Pancreatic Neoplasms (3) · Astrocytoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Thyroid Cancer, Papillary (1) · Urinary Bladder Neoplasms (1)
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Site (3) · Pancreatic Diseases (3) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Gemcitabine (1) · NUC-1031 (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · tovorafenib (1)
Day One Biopharmaceuticals, Inc. (1) · ParVation Therapeutics, Inc. (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1)
United States (2) · Australia (1) · Belgium (1) · Canada (1) · France (1) · South Korea (1) · Spain (1) · United Kingdom (1)